Lexicon Pharmaceuticals | LXRX - Selling And Administration Expenses


Lexicon Pharmaceuticals reported $3.98M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Abbott USD 3.13B 125M Dec/2025
Acadia Pharmaceuticals USD 146.73M 21.82M Dec/2025
Agios Pharmaceuticals USD 42.97M 1.7M Dec/2025
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
BioMarin Pharmaceutical USD 322.21M 98.79M Dec/2025
Coherus Biosciences USD 15M 6.26M Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Esperion Therapeutics USD 39.42M 456K Dec/2025
Halozyme Therapeutics USD 64.64M 27.11M Dec/2025
Illumina USD 283M 27M Dec/2025
Insmed USD 212.48M 26.11M Dec/2025
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
J&J USD 6.75B 831M Dec/2025
Lexicon Pharmaceuticals USD 3.98M 195K Dec/2025
MacroGenics USD 7.94M 1.96M Dec/2025
MannKind USD 29.09M 2.53M Sep/2025
Merck USD 2.85B 215M Dec/2025
Moderna USD 308M 40M Dec/2025
Novartis USD 3.44B 128M Dec/2025
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Sarepta Therapeutics USD 105.38M 28.27M Dec/2025
Thermo Fisher Scientific USD 1.98B 182M Dec/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
United Therapeutics USD 190.6M 38.6M Dec/2025
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024